Cascade genetic testing utilized only in 31% of initial families with pathogenic variants in breast cancer genes
The study by the Genekor Scientific Team on "Cascade genetic testing utilized only in 31% of initial families with pathogenic variants in breast cancer genes" was presented at ESMO CONGRESS 2022 in the form of a Poster by Doctors Ziogas Dimitrios (Pathologist-Oncologist A Oncology Clinic Laiko Athens General Hospital) and Giassas Stylianos (Pathologist-Oncologist, Director B, Oncology Clinic, Iasso Hospital).
read more